This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.00% per year. These returns cover a period from January 1, 1988 through May 4, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
GSK to Strengthen Oncology Pipeline With $10.6B Nuvalent Buyout
by Zacks Equity Research
GSK buys Nuvalent for $10.6 billion, adding three lung cancer pipeline candidates and expanding its precision oncology presence.
GSKPositive Net Change RPRXPositive Net Change NUVLPositive Net Change
biotechs medical pharmaceuticals
Can Eli Lilly's Clinical Momentum Keep the Stock at Record Highs?
by Ahan Chakraborty
LLY stock hits a new all-time high as data from phase III studies show Foundayo outperforming rivals and retatrutide delivering strong weight-loss and diabetes results.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Sanofi Wins EU Nod for Subcutaneous Sarclisa in Multiple Myeloma
by Zacks Equity Research
SNY wins EU approval for a subcutaneous Sarclisa option in multiple myeloma, offering faster administration and flexible delivery methods.
SNYPositive Net Change BMYPositive Net Change AMGNPositive Net Change
biotechs medical pharmaceuticals
ALT and the Rise of Dual Agonists Targeting Liver Disease
by Zacks Equity Research
Altimmune's dual-agonist pemvidutide faces key 2026 tests in MASH and alcohol-related diseases that could validate its multi-pathway liver strategy.
NVOPositive Net Change LLYPositive Net Change ALTNegative Net Change
biotechs
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup
by Zacks Equity Research
Altimmune is betting on pemvidutide across MASH and alcohol-related liver diseases, with key 2026 data and a planned Phase III launch shaping its path.
NVOPositive Net Change LLYPositive Net Change ALTNegative Net Change
biotechs
Roche, Nurix Team Up to Advance BTK Degrader Bexobrutideg
by Zacks Equity Research
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into immunology and neurology.
RHHBYPositive Net Change NVOPositive Net Change LLYPositive Net Change NRIXPositive Net Change
biotechnology biotechs medical pharmaceuticals
Is Altimmune Worth Buying Ahead of 2026 Catalysts?
by Zacks Equity Research
ALT faces a catalyst-packed 2026, with a pivotal MASH study launch and alcohol-use-disorder data set to test pemvidutide's multi-indication story.
NVOPositive Net Change LLYPositive Net Change ALTNegative Net Change MDGLPositive Net Change
biotechs
Novo Nordisk Real-World Data Supports Ozempic Against LLY's Mounjaro
by Zacks Equity Research
NVO says real-world data show Ozempic 2 mg matches Eli Lilly's Mounjaro on glucose control and is linked to a higher likelihood of meaningful weight loss.
NVOPositive Net Change LLYPositive Net Change LQDAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can Wegovy Pill's Rapid Uptake Give Novo Nordisk an Edge Over LLY?
by Ahan Chakraborty
NVO's oral Wegovy launch is off to a blistering start, topping 3 million prescriptions in five months and drawing many first-time GLP-1 users.
NVOPositive Net Change LLYPositive Net Change VKTXPositive Net Change GPCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
AGEN Early Access Revenues Signal a New Path Ahead of Approval
by Sundeep Ganoria
Agenus turns early physician demand for BOT+BAL into revenues and real-world data, testing its launch strategy before formal approval.
BMYPositive Net Change MRKPositive Net Change AGENPositive Net Change
biotechs medical pharmaceuticals